That opens a path to future studies to further characterize groups of patients with common features in the context of pharmacogenetics and in an era towards developing a more precise personalized treatment with IL-5Rα as a therapeutic target for CRSwNP. Here, IL5RA is linked to chronic rhinosinusitis with nasal polyps.